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ABSTRACT: Noonan syndrome (NS) is a relatively com-
mon developmental disorder with a pleomorphic pheno-
type. Mutations causing NS alter genes encoding proteins
involved in the RAS-MAPK pathway.We and others iden-
tified Casitas B-lineage lymphoma proto-oncogene (CBL),
which encodes an E3-ubiquitin ligase acting as a tumor
suppressor in myeloid malignancies, as a disease gene un-
derlying a condition clinically related to NS. Here, we
further explored the spectrum of germline CBL mutations
and their associated phenotype. CBL mutation scanning
performed on 349 affected subjects with features over-
lapping NS and no mutation in NS genes allowed the
identification of five different variants with pathological
significance. Among them, two splice-site changes, one
in-frame deletion, and one missense mutation affected the
RING domain and/or the adjacent linker region, overlap-
ping cancer-associated defects. A novel nonsense mutation
generating a v-Cbl-like protein able to enhance signal flow
through RAS was also identified. Genotype–phenotype
correlation analysis performed on available records in-
dicated that germline CBL mutations cause a variable
phenotype characterized by a relatively high frequency
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of neurological features, predisposition to juvenile
myelomonocytic leukemia, and low prevalence of cardiac
defects, reduced growth, and cryptorchidism. Finally, we
excluded a major contribution of two additional members
of the CBL family, CBLB and CBLC, to NS and related
disorders.
Hum Mutat 36:787–796, 2015. C© 2015 Wiley Periodicals, Inc.
KEY WORDS: CBL mutation-associated syndrome; Noo-
nan syndrome; RAS-MAPK; genotype–phenotype corre-
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Introduction
Noonan syndrome (NS; MIM #163950) is an autosomal-
dominant, relatively common, and clinically variable conditionwith
an estimated prevalence of one in 1,000–2,500 live births [Mendez
andOpitz, 1985]. It is characterized bypostnatal reduced growth, fa-
cial dysmorphism, and congenital heart defects (CHDs) [Allanson,
2007; van der Burgt, 2007; Roberts et al., 2013]. Although the facial
dysmorphia changes with age, themost recurrent features consist of
a broad forehead, hypertelorism, downslanting palpebral fissures,
ptosis, epicanthal folds, and low-set, posteriorly rotated ears with
thick helices. Apart from Down syndrome, NS is the most com-
mon syndromic cause of CHDs [Burch et al., 1993; Marino et al.,
1999; Shaw et al., 2007]. Cardiac involvement is present in up to
80% of affected individuals, with pulmonary valve stenosis, hyper-
trophic cardiomyopathy (HCM), and septal defects occurring most
commonly. Other associated features include chest and spine de-
fects, ectodermal anomalies, webbed/short neck, variable cognitive
deficits, cryptorchidism, delayed puberty, lymphatic dysplasia, and
a wide spectrum of hematologic abnormalities, including transient
monocytosis, coagulation defects, and, rarely, certain malignancies
of infancy and childhood [Tartaglia et al., 2003; Jongmans et al.,
2011; Kratz et al., 2011; Aoki and Matsubara, 2013].
C© 2015 WILEY PERIODICALS, INC.
NS is genetically heterogeneous. Extensive studies performed in
the last decade demonstrated that all the genes implicated in NS and
related phenotypes encode proteins with a role in the RAS signal-
ing, with disease-causingmutations generally enhancing signal flow
through the MAPK cascade but also perturbing signal flow through
other RAS-mediated pathways [Tartaglia et al., 2011]. Germline
missense, gain-of-function mutations in PTPN11, which encodes
SHP2, a cytoplasmic protein tyrosine phosphatase that functions
as a positive regulator of RAS signaling [Neel et al., 2003], occur
in approximately 50% of NS subjects [Tartaglia et al., 2001, 2002].
Activating mutations in seven additional genes coding for trans-
ducers or modulatory proteins participating in this pathway (i.e.,
SOS1, KRAS, NRAS, RIT1, RAF1, BRAF, and MAP2K1) account
for an additional one-fourth of cases [Tartaglia et al., 2011; Aoki
et al., 2013]. Remarkably, mutations in the same genes and other
functionally related loci have been reported to underlie a group of
clinically related conditions, which have been collectively named
“RASopathies” [Aoki et al., 2008; Tartaglia and Gelb, 2010; Rauen,
2013; Flex et al., 2014].
We and others recently reported that germline mutations in the
Casitas B-lineage lymphoma proto-oncogene (CBL; MIM #165360)
cause a previously unrecognized condition that resembles NS phe-
notypically and predispose to juvenile myelomonocytic leukemia
(JMML; MIM #607785) (CBL mutation-associated syndrome,
hereinafter) [Martinelli et al., 2010; Niemeyer et al., 2010; Pe´rez
et al., 2010]. CBL encodes a RING finger E3 ubiquitin ligase that
negatively regulates intracellular signaling, targeting receptor tyro-
sine kinases (RTKs) for internalization and recycling/degradation
[Swaminathan and Tsygankov, 2006; Dikic and Schmidt, 2007]. On
the other hand, CBL positively modulates signal traffic through its
adaptor function. Somatically acquired CBL mutations occur with
variable prevalence in myeloid malignancies, including JMML, and
are generally observed as homozygous lesions due to loss of thewild-
type allele by acquired isodisomy of the 11q23 chromosomal region
[Kales et al., 2010]. Collected data indicate that disease-associated
mutations are predominantly splice site or missense changes affect-
ing exons 8 and 9, which encode the RINGfinger domain and/or the
adjacent linker helix region (LHR) connecting this domain to the
N-terminal tyrosine kinase binding (TKB) domain. In line with
studies focused on cancer-associated CBL mutations [Sargin et al.,
2007; Sanada et al., 2009; Martinelli et al., 2012], functional
characterization of a panel of RASopathy-causing mutants docu-
mented that lesions act in a dominant-negative manner, affecting
CBL-mediated receptor ubiquitination, and upregulate signal flow
through RAS [Martinelli et al., 2010; Niemeyer et al., 2010; Brand
et al., 2014].
CBL mutation-associated syndrome is characterized by pheno-
typic heterogeneity and variable expressivity. Here, we further in-
vestigated themolecular spectrumof germlineCBLmutations, their
impact on protein function, and the clinical features associated with
those molecular lesions.
Materials and Methods
Patients
Two cohorts consisting of clinically well-characterized subjects
with a clinical diagnosis of NS or features within the RASopathy
phenotypic spectrum were included in the study. A first group of
patients (N = 214) were negative for mutations in genes previously
identified to cause NS or a closely related condition (i.e., PTPN11,
SOS1, KRAS, NRAS, RIT1, RAF1, BRAF, MAP2K1, SHOC2, and
RRAS). In the second cohort (N = 135), mutations in a subset of
disease genes had been excluded (i.e., PTPN11, SOS1, RAF1, RIT1,
KRAS, and SHOC2). Nearly all patients of both cohorts were of
European ancestry. Subjects were assessed by experienced clinical
geneticists and pediatricians. Clinical assessment included physical,
anthropometric, neurologic, and cardiac evaluations, as well as ac-
curate examination of craniofacial features, and ophthalmologic,
immunologic, ectodermal, and skeletal defects. DNA samples and
clinical data were collected under research protocols approved by
an institutional review board, and informed consent for genetic
analyses was obtained from all patients.
Mutation Analysis
Genomic DNA was isolated from peripheral blood leukocytes
and other tissues, according to standard procedures. The entire
CBL coding sequence (NM 005188.3), as well as the exon/intron
boundaries and flanking intronic portions, were scanned for
mutations by direct sequencing or DHPLC analysis. Sequencing
used the ABI BigDye Terminator Sequencing Kit v.1.1 (Applied
Biosystems, Foster City, CA) and an ABI 3700 Capillary Array
Sequencer or ABI 3500 Genetic Analyzer (Applied Biosystems).
DHPLC screening was performed using the 3100 and/or 3500HT
Wave DNA Fragment Analysis System (Transgenomic, Omaha,
NE), at column temperatures recommended by the Navigator
version 1.5.4.23 software (Transgenomic), as previously described
[Martinelli et al., 2010]. Amplimers having abnormal elution
profiles were reamplified, purified (Qiagen, Hilden, Germany), and
sequenced bidirectionally. Homozygous/hemizygous condition
for CBL sequence variations was explored by DHPLC analysis
using pooled DNAs. Primer pair sequences, and PCR and DHPLC
settings are available upon request. Nucleotide numbering of the
mutations and exonic disease-unrelated variants reflects cDNA
numbering, with 1 corresponding to the A of the ATG translation
initiation codon in the reference sequence (NM 005188.3), whereas
position of the intronic variants were numbered according to the
reference genomic sequence (NG 016808.1).
Mutational screening was also performed on exons 8 and 9 of
CBLB (NM 170662.3), and exons 7 and 8 of CBLC (NM 012116.3).
Primer sequences are listed in Supp. Table S1.
When available, parental DNAs were sequenced to establish
whether the identified changes in sporadic cases were de novo.
Paternity was confirmed using the AmpDESTER ProfilerPlus kit
(Applied Biosystems).
Molecular Characterization of Splice-Site Mutations
Total RNAwas isolated from circulating leukocytes of case 12520-
1byRNeasyMiniKit (Qiagen).Reverse transcriptionwasperformed
using the SuperScriptIII first strand kit (Invitrogen, Carlsbad, CA),
following the manufacturer’s instructions. RT-PCR was carried out
using primers designed to amplify exons 7–9 of CBL. Primer se-
quences are listed in Supp. Table S2. The length of each transcript
was determined by cloning purified RT-PCR products in a pCR
2.1 TOPO vector (Qiagen). Individual Escherichia coli colonies were
amplified, and amplicons were separated by electrophoresis on 2%
agarose gel, and sequenced.
RNA was not available for case 827-10. To characterize the effect
of the c.1096-1G>T mutation on mRNA processing, we generated
wild-type and mutant minigenes, using the exon trapping vector
pSPL3 (Life Technologies, Monza, Italy). A genomic DNA fragment
encompassing exons 7–9 of CBL (Chr11:119147899–119149924)
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was amplified by using Intron 6 Fw and Intron 9 Rv primers in-
cluding the XhoI and NheI restriction sites, respectively (Supp. Ta-
ble S2). PCR amplification was performed using the Platinum Taq
DNA Polymerase (Invitrogen). The resulting 2,025-bp-length PCR
product was purified, digested, and cloned into the pSPL3 vector.
The correct sequence of the fragment of interest was confirmed by
direct sequencing. COS1 cells were transiently transfected with 4μg
of wild-type or mutant constructs using Fugene 6 (Promega, Milan,
Italy). Twenty-four hours after transfection, cells were harvested, to-
tal RNA was extracted, and reverse transcription was performed as
described above. The resulting cDNAs were amplified using pSPL3-
specific primers (SD6 and SA2) and primers to amplify CBL exons
7–9. PCR conditions are available upon request.
Functional Studies
The c.705T>A nucleotide substitution was introduced in the
N-terminally hemagglutinin (HA)-tagged human CBL cDNA
cloned in the pALTER-MAX vector (Promega) by site-directed
mutagenesis (QuikChange Kit; Stratagene, La Jolla, CA). COS1 cells
were transiently transfected with wild-type or mutant CBL (4 μg),
by using Fugene 6 (Promega). Twenty-four hours post-transfection,
cells were serum-starved (16 hr) and then stimulated with EGF (Life
Technologies) (100 ng/ml, 30 min). ERK and AKT phosphorylation
assays were performed in cells transiently expressing the p.Tyr235∗,
p.Arg420Gln, and wild-type CBL proteins, as previously described
[Martinelli et al., 2010, 2012]. Protein phosphorylation status
(pERK1/2 #9106 and pAKT #9271S; Cell Signaling, Danvers, MA)
was evaluated basally or after EGF stimulation. ERK1/2 (Cell
Signaling, #9102), AKT (Cell Signaling, #9272), CBL (anti-HA
antibody; H3663; Sigma–Aldrich, St. Louis, MO) and β-tubulin
(T4026; Sigma–Aldrich) expression levels were measured. For
time course analysis of CBL stability, 24 hr after transfection,
COS1 cells were treated with cycloheximide (Sigma–Aldrich)
at 100 μg/ml to prevent protein synthesis, at the indicated
times.
Statistical Analysis
P values for genotype–phenotype correlation analyseswere calcu-
lated using two-tailed Fisher’s exact test. The significance threshold
was set at P = 0.05. Exact confidence intervals of proportions (at
95% level) were calculated based on binomial distribution.
Results
Mutation Analysis and Functional Characterization of
Mutations
Three-hundred and forty-nine subjects with clinical diagnosis
of NS or having features suggestive of this disorder or within the
RASopathy phenotypic spectrum, and without mutations in pre-
viously identified NS disease genes were included in the study.
Mutation analysis allowed the identification of heterozygosity for
a CBL mutation in five unrelated individuals (Fig. 1A; Table 1)
with a variable phenotype overlapping NS only in part (Supp. Table
S3) (NS EuroNet database, https://nseuronet.com/php/index.php).
The c.1111T>C (case 10-0746) and c.1104 1112del (case 13M1230)
mutations (p.Tyr371His and p.Glu369 Tyr371del, respectively), as
well as the c.1096-4 1096-1delAAAG (case 12520–1) and c.1096-
1G>T (case 827-10) splice-site variants were identified in four spo-
radic cases. Among these, parental DNA was available for three
patients, and sequencing of the relevant exon demonstrated the
de novo origin of mutations (Table 1). In cases for which DNA
from other tissues was available, the CBL lesion was documented
in oral mucosal epithelial (c.1111T>C) or muscle (c.1096-4 1096-
1delAAAG) cells, which excluded a somatic event restricted to
hematopoietic cells (Supp. Fig. S1). The c.705T>A substitution in
exon 4 was documented in a child (case 05-0562) whose mother
and brother showed features within the RASopathy spectrum. DNA
specimens from these family members were not available to an-
alyze cosegregation of the mutation with disease. This change,
however, was not observed in more than 400 population-matched
unaffected individuals scanned by DHPLC analysis and direct se-
quencing, indicating that this variant does not represent a com-
mon disease-unrelated polymorphism occurring in the population.
Consistently, this variant had not been reported in public databases
(dbSNP138, ExAC, and 1000 genomes). A full list of the disease-
unrelated changes, including silent substitutions and intronic vari-
ants close to the intron/exon boundaries, is reported in Supp. Table
S4. Given the close homology and functional relationship occurring
among the three members of the CBL family [Swaminathan and
Tsygankov, 2006], the exons of CBLB (MIM #604491) and CBLC
(MIM #608453) encompassing the sequence encoding the RING
finger domain and the LHR,which represent themutational hotspot
regions for CBL (see below), were analyzed in a subset of 96 sub-
jects within the first cohort. Mutation scanning failed in identifying
any disease-causing lesion in these genes, indicating that CBLB and
CBLC are not commonly mutated in RASopathies.
The p.Tyr371His and p.Glu369 Tyr371del mutations involve
residues evolutionarily conserved in CBL orthologs and paralogs
located within the LHR, a region frequently affected by somatic
and germline CBL lesions (Fig. 1B). Homozygous defects involving
Tyr371 are the most common event among CBL mutation-positive
individuals with nonsyndromic JMML [Loh et al., 2009; Mura-
matsu et al., 2010; Niemeyer et al., 2010]. Leukemia-associated
mutations affecting Tyr371 were previously shown to abolish
RTKs ubiquitination by impairing E3 activity [Levkowitz et al.,
1999; Thien et al., 2001; Sanada et al., 2009; Niemeyer et al.,
2010], promote cytokine-independent growth and constitutive
activation of downstream signaling pathways (i.e., RAS-MAPK
and PI3K-AKT) [Niemeyer et al., 2010], and confer oncogenic
properties [Kassenbrock and Anderson, 2004; Sanada et al., 2009].
Likewise, p.Glu369 Tyr371del, which had been reported as a
somatic event associated with 11q-aUPD in a subject with chronic
myelomonocytic leukemia (CMML) [Sanada et al., 2009], is
expected to be functionally equivalent tomutations affecting Tyr371.
Both the c.1096-4 1096-1delAAAG and c.1096-1G>T lesions
affect the CBL splice acceptor site for exon 8. Splice-site mutations
affecting introns 7 and 8 account for approximately 10% of CBL
defects underlying myeloid malignancies [Kales et al., 2010], and
are predicted to encode a protein that lacks essential regions
of the LHR and/or the RING finger domain. RT-PCR analysis
performed on cDNA obtained from total RNA extracted from
circulating leukocytes of patient 12520-1 documented aberrant
processing of the transcript. Besides the wild-type allele, three
smaller products resulting from partial or complete deletion of
exon 8 were identified (Fig. 2A and C; Supp. Fig. S2). Interestingly,
products 1A and 1B resulted from the use of two alternative splice
acceptor sites within exon 8 (c.1118 1119 or c.1166 1167), leading
to deletion of the first 8- or 24-hr residues encoded by this exon.
The c.1096-1G>T transversion found in case 827-10 had not been
previously described, but a different change at the same position
(c.1096-1G>C) had been reported [Abbas et al., 2008; Grand et al.,
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Figure 1. RASopathy-associated germline CBL mutations. A: Electropherograms showing the heterozygous CBL mutations identified in the
present study. Nucleotide deletions are shown in open boxes. B: Location of germline disease-associated lesions is shown above the CBL domain
structure scheme (splice-site changes are shown as green-filled peaks). Forty-four germline CBL mutations have been identified to date. Amino
acid changes at codons 371 and 367 have been reported in 18 and four unrelated cases, respectively; mutations at codons 390, 418, and 420, and
the c.1228-2A>G splice-site change, have been found in two cases; all the other substitutions were described once. The N-terminal tyrosine kinase
binding domain (TKB) (red), linker helix region (LHR) (light gray), RING-finger domain (RING) (orange), and ubiquitin-associated and leucine zipper
domain (UBA/LZ) (dark gray), are shown. The distribution of somatic CBL missense (blue-filled peaks), nonsense (red-filled peaks), and splice-site
(green-filled peaks) mutations occurring in leukemia is shown below the cartoon (Cosmic database). C: Facial features of two affected subjects
carrying the c.705T>A (p.Tyr235∗) and the c.1111T>C (p.Tyr371His) mutations.
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Table 1. List of Previously Reported and Newly Identified Germline CBL Gene Mutations
Number
of cases
Nucleotide
changea Exon
Predicted amino
acid change Domain
Zygosity
hematopoietic
cells
Zygosity non-
hematopoietic
cells
Origin of
the
mutation Reference
1 c.705T>A 4 p.Tyr235∗ TKB Heterozygous NA Familial Present study
1 c.1096-1G>C Intron
7
Splice-site change LHR/RINGb Homozygous Heterozygous NA Niemeyer et al. (2010)
1 c.1096-1G>T Intron
7
Splice-site change LHR/RINGb Heterozygous NA De novo Present study; Bu¨low
et al. (2015)
1 c.1096-1delGG Intron
7
Splice-site change LHR/RINGb Heterozygous Heterozygous De novo Strullu et al. (2013)
1 c.1096-4 1096-
1delAAAG
Intron
7
Splice-site change LHR/RINGb Heterozygous Heterozygous NA Present study
4 c.1100A>C 8 p.Gln367Pro LHR Heterozygous Heterozygousc De novo Bu¨low et al. (2015);
Martinelli et al.
(2010); Hanson et al.
(2014)
1 c. 1104 1112del 8 p.Glu369 Tyr371del LHR Heterozygous Heterozygous De novo Present study
1 c.1111T>A 8 p.Tyr371Asn LHR Homozygous Heterozygous NA Niemeyer et al. (2010)
15 c.1111T>C 8 p.Tyr371His LHR Homozygous Heterozygous De novod Niemeyer et al. (2010);
Strullu et al. (2013);
Pe´rez et al. (2010);
Hyakuna et al. (2015)
1 c.1111T>C 8 p.Tyr371His LHR Heterozygous Heterozygous De novo Present study
1 c.1112A>G 8 p.Tyr371Cys LHR Homozygous Heterozygous Familial Niemeyer et al. (2010)
1 c.1139T>C 8 p.Leu380Pro LHR Homozygous Heterozygous NA Niemeyer et al. (2010)
1 c.1141T>G 8 p.Cys381Gly LHR Homozygous Heterozygous De novo Strullu et al. (2013)
1 c.1144A>G 8 p.Lys382Glu RING Heterozygous Heterozygous Familial Martinelli et al. (2010)
1 c.1150T>C 8 p.Cys384Arg RING Homozygous Heterozygous Familial Niemeyer et al. (2010)
1 c.1168G>T 8 p.Asp390Tyr RING Heterozygous Heterozygous De novo Martinelli et al. (2010)
1 c.1169A>T 8 p.Asp390Val RING Homozygous Heterozygous De novo Becker et al. (2014)
1 c.1186T>C 8 p.Cys396Arg RING Homozygous Heterozygous NA Niemeyer et al. (2010)
1 c.1193A>G 8 p.His398Arg RING Homozygous Heterozygous Familial Niemeyer et al. (2010)
1 c.1210T>C 8 p.Cys404Arg RING Homozygous Heterozygous De novo Niemeyer et al. (2010)
1 c.1222T>A 8 p.Trp408Arg RING Homozygous Heterozygous De novo Niemeyer et al. (2010)
2 c.1228-2A>G Intron
8
Splice-site change RINGb Homozygous NA De novo Niemeyer et al. (2010);
Strullu et al. (2013)
1 c.1253T>C 9 p.Phe418Ser RING Homozygous Heterozygous Familial Strullu et al. (2013)
1 c.1254C>G 9 p.Phe418Leu RING Homozygous Heterozygous Familial Strullu et al. (2013)
1 c.1258C>G 9 p.Arg420Gly RING/linker2 Homozygous Heterozygous De novo Strullu et al. (2013)
1 c.1259G>A 9 p.Arg420Gln RING/linker2 Heterozygous Heterozygous Familial Martinelli et al. (2010)
aPosition referred to the A of the ATG translation initiation codon in the reference cDNA sequence (NM_005188.3).
bAberrant mRNA processing was demonstrated, leading to a catalytically inactive protein missing a portion of both the RING domain and the linker helix region connecting it to
the TKB domain (mutations affecting intron 7), or the RING domain alone (mutation affecting intron 8).
cIn the subject described by Hanson et al. (2014), the c.1100A>C mutation was found in an homozygous state in three independent teratoma samples. Nonhematopoietic cells
were not available in two subjects carrying this lesion.
dThis mutation occurred as a de novo event in eight subjects, whereas it was inherited in six cases.
LHR, linker helix region connecting the RING finger domain to the TKB domain; linker2, stretch connecting the RING finger domain to the proline-rich domain; NA, data not
available; RING, RING finger domain; TKB, N-terminal tyrosine kinase-binding domain.
2009; Loh et al., 2009; Niemeyer et al., 2010]. Since RNA was not
available for this patient, a minigene assay was performed to explore
the consequences of the c.1096-1G>T variant on mRNA processing
[Cooper, 2005]. COS1 cells were transiently transfected with the
pSPL3 constructs containing either the wild-type or mutant CBL
genomic region encompassing exon 8. Sequencing of the processed
transcript RT-PCR products revealed aberrant splicing of the mu-
tant allele, resulting in loss of the entire exon 8 (Fig. 2B and C; Supp.
Fig. S2).
The c.705T>A transversion found in case 05-0562 is predicted to
cause premature termination of the protein at codon 235, within
the TKB domain, possibly generating a v-Cbl-like protein lacking
E3 activity [Langdon et al., 1989; Blake et al., 1991]. RNA was not
available to evaluate the extent of reduction in the level of mRNA of
the transcribed mutant allele due to nonsense-mediated decay. To
explore the effect of this change on protein expression and stability
in vitro, and evaluate its impact on signal flow through the RAS-
MAPKandPI3K-AKTcascades,we transiently expressedHA-tagged
CBLWT, CBLTyr235∗, and CBLArg420Gln proteins, the latter included as
representative of CBL mutants acting in a dominant-negative man-
ner [Sargin et al., 2007; Dunbar et al., 2008; Martinelli et al., 2010],
in COS1 cells. Western blot analysis showed a dramatically reduced
expression of the CBL Tyr235∗ mutant compared with the wild-type
protein (Fig. 3A), which was due to quick protein degradation (half-
life <2 hr) as documented by cycloheximide treatment experiments
(Fig. 3B). Cells expressing the CBLTyr235∗ mutant, however, showed
enhanced constitutive and EGF-induced ERK and AKT phosphory-
lation (Fig. 3C), suggesting a dominant-negative effect on wild-type
CBL, possibly uncoupling cell-surface receptor binding to E3 ligase
activity.
Clinical Features of CBL Mutation-Positive Subjects
Detailed clinical information was obtained for the five subjects
harboring the germline CBL mutations (Supp. Table S3), and pic-
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Figure 2. Consequences of the c.1096-4_1096-1delAAAG and c.1096-
1G>T splice-site changes on mRNA processing. A: RT-PCR products
obtained from cDNA of case 12520-1 (c.1096-4_1096-1delAAAG). PCR
products were cloned, individual Escherichia coli colonies were ampli-
fied, and amplicons were separated by electrophoresis on 2% agarose
gel. Wild-type (WT) amplicon (296-bp-long, lane 3) was observed in 17
out of 25 colonies, whereas the 1A (272-bp-long, lane 4), 1B (224-bp-
long, lane 5), and 1C (164-bp-long, lane 2) products were identified in
four, three, and one clones, respectively. B: Minigene assay performed
to evaluate the impact of the c.1096-1G>T change (case 827-10). COS1
cells were transiently transfected with wild-type (WT) or mutant con-
struct and lysed. cDNAs obtained from total RNAwas amplified with the
same primer pair used in panel A. Lane 1, ladder; lane 2, mutant allele
(M); lane 3,WTallele.C: Schematic representation of the consequences
of the splice-site mutations detected in patients 12520-1 and 827-10 (see
Supp. Fig. S2 for chromatograms).  indicates deleted region.
tures were available for two of them (Fig. 1C). All patients dis-
played dysmorphic facial features within the RASopathy spectrum.
The sporadic case heterozygous for the c.1111T>C transition was
referred at 5 years because of moderate bilateral sensorineural hear-
ing loss requiring hearing aids, mild developmental delay, and lan-
guage difficulties (Wechsler Intelligence Scale for Children-Revised
[WISC-R], IQ = 64, verbal = 58, performance = 74). Clinical exam-
ination at 10 years showed relative macrocephaly, short neck, mild
pectus excavatum, widely spaced nipples, curly hair, dark skin, and
a single cafe´-au-lait spot on the left leg. Stature was in the nor-
mal range and cardiologic evaluation did not reveal any relevant
defect. A head MRI scan showed a widened cisterna magna and
cerebellar vermis hypoplasia associated with tortuosity of intracra-
nial arteries. Despite the well-documented association between the
c.1111T>C nucleotide change and JMML, this subject did not ex-
hibit any hematologic anomaly.
The boy carrying the de novo c.1104 1112del mutation exhib-
ited congenital left-sided cataract that had been diagnosed during
the neonatal period. Echocardiography revealed mild pulmonary
valve stenosis requiring no specific treatment. He was operated for
inguinal hernia and undescended testis at the age of 18 months.
No hematologic abnormality was ever noted. Psychomotor devel-
opment was significantly delayed (walking at 30 months). At the
age of 35 months, his height was 91.5 cm (10th percentile), weight
was 14.1 kg (50th percentile), and head circumference was 48 cm
(3rd percentile). When he was admitted for genetic re-evaluation at
the age of 3 years and 2 months, he was noted to have asymmetric
thorax and relatively dark skin pigmentation.
The girl heterozygous for the c.1096-4 1096-1delAAAG splice-
site change had an unremarkable family history. At birth, she was
hydropic and profoundly hypotonic with no respiratory effort, and
required immediate resuscitation and intubation. She exhibited se-
vere respiratory acidosis,markedbilateral pleural effusions, and chy-
lothorax, andwas found tobe at grade2of Sarnat’s hypoxic-ischemic
encephalopathy scale. Her physical examination revealed diffuse
cyanosis, anasarca, mild strabismus, redundant skin on the neck,
shield chest with widely spaced nipples, extremities joint limita-
tions, left hand single palmar crease, hammer toes, high arched feet,
and diffuse petechiae on face and upper body. Cardiac evaluation re-
vealed pulmonary valve stenosis and biventricular hypertrophywith
severe left outflow obstruction. Neurological examination demon-
strated severe hypotonia with limited spontaneous activity. Brain
ultrasound showed increased white matter echogenicity and mildly
underdeveloped sulci in the brain parenchyma. She also exhibited
hepatosplenomegaly andbilateral hydronephrosis andhydroureters.
Blood count showed persistent leukocytosis, monocytosis, and
thrombocytopenia, whereas bone marrow aspirate presented ele-
vated blast count with no evidence of chromosome rearrangements.
On liver biopsy, therewasprominent extramedullaryhematopoiesis,
supporting a diagnosis of JMML. Head circumference and linear
growth decelerated quickly, settling below the 3rd percentile. At the
ageof 5months, neurodevelopmental assessmentsdemonstrated ev-
idence of global developmental delay with poor interaction with the
environment and delayedmotor skills. Severely bradycardic and hy-
potensive, she died at the age of 6 months. Autopsy revealed diffuse
edema, bilateral pulmonary effusions, extensive multifocal fibro-
sis, and perivascular infiltrates of nucleated erythroid and myeloid
precursor cells, suggestive of extramedullary hematopoiesis.
The boy heterozygous for the c.1096-1G>T splice-site variant had
a history of prenatal pleural effusions/hydrops. Clinical details had
recently been reported in a separate study focused on prenatal find-
ings associated with germline CBL mutations [Bu¨low et al., 2015].
Major postnatal features included severe feeding difficulties, failure
to thrive, short stature, hypotonia, and psychomotor retardation.
Splenomegaly and easy bruising without any evidence of a hema-
tologic neoplasia persisted up to the age of 11 years, when he was
last examined. Cardiac evaluation revealed mild pulmonary valve
stenosis. He also showed a broad chest with mild pectus excavatum
and carinatum, and hyperpigmentation of the legs. Brain MRI re-
vealed delayed myelination, hypoplasia of the olfactory bulbs, and
optic chiasm.
Finally, the boy carrying the heterozygous c.705T>A transver-
sion was the second child of nonconsanguineous parents, appeared
macrosomic (at 7 months, weight and length were at 90th and 97th
percentile, respectively), but had a head circumference at the 3rd
percentile. He displayed short neck with redundant skin. Develop-
mental milestones were normal. Two-dimensional color-Doppler
echocardiography revealed pulmonary valve stenosis with dysplastic
pulmonary valve leaflets andpoststenotic pulmonary dilation.Cere-
bral, renal, ophthalmological, and audiological assessments were
normal. Clinical evaluation of the affected mother (35-year old)
and brother (4.3-year old) documented high forehead, downslant-
ing palpebral fissures, thick lips, low-set, and dysmorphic ears with
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Figure 3. Functional characterization of the CBLTyr235∗ mutant. A: Expression levels of exogenous CBL in COS1 cells transiently expressing wild-
type CBL, and the CBLArg420Gln and CBLTyr235∗ mutants. Whole cell extracts were probed with anti-HA and anti-β-tubulin antibodies. B: Time course
analysis of CBL stability after cycloheximide treatment. Twenty-four hours following transfection, COS1 cells were treated with cycloheximide at
100μg/ml to prevent protein synthesis, at the indicated times, and probedwith anti-HA and anti-β-tubulin antibodies. Blot with the truncatedmutant
(right panel) was exposed four times longer than that displaying the wild-type and p.Arg420Gln proteins (left panel) to appreciate the expression
levels of the former. C: Determination of ERK and AKT phosphorylation levels in transiently transfected COS1 cells. Protein phosphorylation status
(pERK1/2 and pAKT) was evaluated basally or following EGF stimulation (100 ng/ml, 30 min). Total ERK and AKT levels in cell lysates are shown for
equal protein expression and loading. Representative blots of three performed experiments are shown.
thick helices, and low-posterior hairlines. The proband’s brother
also showed a flat nasal bridge, palpebral ptosis, hyperkeratosis, and
short neck. Both individuals, however, had normal stature and did
not display any cardiac defect.
Clinical Spectrum of CBL Mutations and
Genotype–Phenotype Correlation Analyses
A review of the literature allowed us to collect extensive clinical
data for 13 subjects carrying germline CBL mutations, whereas
incomplete information was available for 18 additional individuals
originally studied on the basis of JMML/AML occurrence (Supp.
Table S3). Overall, analysis of the available clinical records con-
firmed previous observations from our group and others indicating
that CBL mutations are associated with a variable phenotype re-
sembling, in part, NS, and confer predisposition to JMML. Notably,
while a particularly severe phenotype was observed in a small subset
of patients, clinical features appeared quite subtle in the majority
of cases. We noticed a lower prevalence of individuals exhibiting
reduced growth (stature below the 3rd percentile) (11/36 vs. 84/115,
P < 0.0001, Fisher’s exact test), cryptorchidism (5/18 vs. 64/83, P <
0.0002), and cardiac defects (12/36 vs. 132/151, P < 0.0001), com-
pared with what observed in the NS general population [Sarkozy
et al., 2009]. Pulmonary valve stenosis and HCM were detected
in 17% (P < 0.0001) and 8% of cases, respectively. Craniofacial
features were always present but generally mild. Ectodermal and
skeletal involvement was frequently observed, with thin/sparse hair,
cafe´-au-lait spots, and thorax anomalies being the most recurrent
features. Five out of 17 cases reported by Niemeyer et al. (2010)
and one additional patient [Strullu et al., 2013] exhibited juvenile
xanthogranuloma. Interestingly, CBL mutation-positive subjects
displayed a relativelyhigh frequencyofneurological features, includ-
ing psychomotor delay (65%), cognitive delay (35%), andmuscular
hypotonia (50%). Head MRI documented delayed myelination,
abnormal corpus callosum, and cerebellar vermis hypoplasia in two
unrelated individuals, whereas Arnold–Chiari malformation type I,
mild left cerebral atrophy, widened cisterna magna, and moyamoya
disease were reported in one patient each. Recurrent compli-
cations also included ocular anomalies (22%) and hearing loss
(17%).
Discussion
CBL is a widely expressed E3 ubiquitin ligase that negatively reg-
ulates intracellular signaling downstream of RTKs [Swaminathan
and Tsygankov, 2006; Dikic and Schmidt, 2007]. Germline CBL
mutations have been established to cause a previously unrecog-
nized RASopathy with variable phenotype [Martinelli et al., 2010;
Niemeyer et al., 2010; Pe´rez et al., 2010]. In this work, we provided
new data on the molecular spectrum of germline CBL mutations
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and more comprehensively assessed the clinical features associated
with CBL lesions.
Since the discovery of CBL as a RASopathy gene, 44 germline
CBL mutations have been identified. Combined data indicate that
these lesions are predominantly missense changes (82.4%; 95% CI,
69.6%–95.2%) affecting residues located within the RING finger
domain or the LHR. Among those lesions, approximately 50% in-
volves Tyr371, with the p.Tyr371His amino acid substitution being
the most recurrent change. Tyr371 plays a crucial role in the activa-
tion of CBL E3 ligase activity [Dou et al., 2012]. The available crystal
structure data are consistent with a model of CBL functional regu-
lation in which, in the absence of the substrate, the enzyme adopts
an autoinhibited conformation with the TKB domain binding to
the RING finger domain and masking the E2-binding sites. Follow-
ing Tyr371 phosphorylation, the LHR undergoes a conformational
change that abrogates autoinhibition and brings the RING domain
and E2 nearby the substrate-binding site, thus promoting E3 activ-
ity. Extensive studies demonstrated that E3 activation is required
for RTKs ubiquitination [Levkowitz et al., 1999; Thien et al., 2001;
Sanada et al., 2009; Niemeyer et al., 2010]. Consistent with that,
mutations affecting Tyr371 was shown to abrogate the ability of CBL
to ubiquitinate FLT3, KIT, and EGFR [Sanada et al., 2009; Niemeyer
et al., 2010].
Heterozygous variants affecting splicing of CBL have been ob-
served in a significant fraction of cases (11.8%; 95% CI, 0.9%–
22.6%), the majority resulting in loss of the sequence encod-
ing amino acid stretched encompassing Tyr371. In the present co-
hort, case 12520-1 carrying the c.1096-4 1096-1delAAAGmutation,
which disrupts the splice acceptor site for exon 8, exhibited a severe
RASopathy phenotype with JMML. Interestingly, we failed to iden-
tify loss of the wild-type allele in leukemic cells from this subject.
This finding mirrored available data indicating that somatically ac-
quired CBL deletions arising from aberrant splicing are frequently
heterozygous, whereas the vast majority of missense mutations are
homozygous as a consequence of 11q isodisomy [Kales et al., 2010;
Strullu et al., 2013]. In line with this evidence, the splice-site muta-
tions detected in MOLM-13 and MOLM-14 cell lines and NUP98-
HOXD13 transgenic mice were also heterozygous [Caligiuri et al.,
2007; Abbas et al., 2008; Slape et al., 2008; Reindl et al., 2009]. These
findings suggest that in-frame deletions of the LHR/RING domains
of CBL might confer stronger transforming properties than mis-
sensemutations. Further studies are required to test this hypothesis.
One small in-frame indel and a nonsense mutation occurring
in two patients were also identified. While the former, leading to
deletion of three highly conserved residues including Tyr371, had
previously been described in leukemia [Sanada et al., 2009], the
latter is a novel change causing premature termination of the pro-
tein at residue 235, within the calcium-binding EF hand of the
TKB domain. This motif plays a key role in maintaining the TKB
structure, allowing proper binding of the ligase to protein tyrosine
kinases [Lupher et al., 1999; Meng et al., 1999]. Truncating muta-
tions affecting the TKB domain of CBL rarely occur as somatic
events in cancer (COSMIC database, http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic/). In particular, heterozygous non-
sense mutations at codons Gln175 and Arg343 were observed in a
lung carcinoma sample and a CMML subject carrying a concomi-
tant p.Cys384Tyr amino acid change, respectively [Sanada et al.,
2009; Imielinski et al., 2012]. These transcripts coding for truncated
proteins are expected to be recognized and degraded via nonsense-
mediated mRNA decay (NMD), an evolutionary conserved mecha-
nism used by eukaryotes to prevent the production of aberrant pro-
teinswithdeleterious gain-of-functionor dominant-negative effects
[Frischmeyer and Dietz, 1999], suggesting haploinsufficiency as the
underlying molecular mechanism. Accumulating data, however,
document high variability in NMD efficiency [Miller and Pearce,
2014], suggesting that a consistent fraction of these nonsense tran-
scripts might generate v-Cbl-like proteins with dominant-negative
function. v-Cbl, the transforming gene of the Cas NS-1 retrovirus,
is a truncated 357 residue-long CBL protein able to induce B-cell
lymphomas and myeloid leukemia in mice [Langdon et al., 1989;
Blake et al., 1991]. This protein functions in a dominant-negative
manner by uncoupling CBL binding to activated RTKs from their
ubiquitination and degradation. Consistently, our in vitro func-
tional data documented enhanced ERK and AKT phosphorylation
in cells expressing the p.Tyr235∗ mutant.
Extensive studies demonstrate that germline-transmitted and
somatically acquired mutations in RASopathy genes rarely over-
lap [Tartaglia et al., 2011], PTPN11 being the archetypal example
[Tartaglia et al., 2006]. In that case, NS-causing mutations con-
fer milder gain-of-function effects than the cancer-associated le-
sions do, with the former being sufficient to perturb biological
processes that are strictly controlled by SHP2, but inadequate to
deregulate significantly processes that are less strictly controlled by
the phosphatase. Similarly, mutations in NRAS, KRAS, and BRAF
underlying NS and cardiofaciocutaneous syndrome (CFCS; MIM
#115150), aswell as those involvingHRAS inCostello syndrome (CS;
MIM #218040), rarely occur as oncogenic defects [Aoki et al., 2008;
Tartaglia et al., 2011]. Conversely, themolecular spectra of germline
and somatic CBL mutations largely overlap, suggesting that these
lesions have generally milder consequences on development than
cancer-associated mutations in most RASopathy genes. Of note,
however, missense mutations involving Tyr371 have been identified
rarely in subjects with CBLmutation-associated syndrome without
JMML (10% of cases), whereas they represent the most common
lesions among individuals with CBL mutation-positive syndromic
JMML (50% of cases). This observation indicates that patients
carrying a germline defect altering codon 371 are at risk for de-
veloping JMML. Consistent with this, codon 371 represents a “hot
spot” for somatic CBL mutations in isolated JMML, whereas it is
rarely mutated in acute leukemias [Kales et al., 2010].
The present study is in line with our previous estimate of CBL
mutation prevalence, indicating that defects in this gene account
for <1% of subjects with clinical features resembling NS, even
though they might be more common among individuals with
features within the RASopathy phenotypic spectrum. Although
the clinical spectrum associated with CBL mutations is wide,
genotype–phenotype correlations seem to exist. Specifically, CBL
mutation-positive patients exhibit a relatively lower prevalence of
cardiac defects (33%) compared with the general NS population,
for which an estimate of up to 80% has been reported [Burch
et al., 1993; Marino et al., 1999; Shaw et al., 2007; Sarkozy et al.,
2009]. Of note, CHDs were observed in all subjects carrying the
p.Glu367Pro amino acid change (N = 4), whereas only one out of 12
patients with a missense mutation at codon 371, for which clinical
data were available, had a cardiac defect (HCM). Short stature
is a common feature in NS, although adult height is not always
adversely affected. Clinical data revealed that length/stature is less
frequently below the 3rd percentile (31%) in cases with mutated
CBL compared with PTPN11mutation-positive NS subjects (93%)
[Roberts et al., 2013], similar to what reported in individuals with
SOS1 mutations [Tartaglia et al., 2007; Lepri et al., 2011]. Finally,
CBLmutation-positive patients displayed a high frequency of head
MRI findings associated or not with structural brain abnormalities
(54%), which are usually rare in NS, but more frequently occur
in other RASopathies, such as CFCS [Roberts et al., 2006]. Among
these, case 827-10 showed delayed brain myelination, a feature that
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was observed in one subject from our previous cohort [Martinelli
et al., 2010]. Similar anomalies represent a relatively common
feature in CFCS patients with a BRAF mutation [Yoon et al., 2007;
Aizaki et al., 2011]. Of note, conditional ablation of Braf in mouse
neuroglial precursor cells was shown to result in defective myelina-
tion and oligodendrocyte differentiation [Galabova-Kovacs et al.,
2008]. Similarly, loss of Shp2 in the oligodendrocyte lineage, as well
as transgenic expression of a NS-associated Shp2 gain-of-function
allele, results in severe abnormal myelination phenotypes [Ehrman
et al., 2014]. Hence, the myelination defect observed in some
individuals with a CBLmutation adds support to the impact of dys-
regulated RAS signaling on glial cell development. Of note, patient
10-0746 and case HD316 from our previous cohort [Martinelli
et al., 2010] showed cerebellar vermis hypoplasia, an unreported
feature in RASopathies. Besides these atypical findings, additional
brain anomalies (e.g., Arnold–Chiari malformation type I,
hypoplastic corpus callosum, mild brain atrophy, and cerebrovas-
cular defects) occur more frequently in NS and related disorders
[Schon et al., 1992; Ganesan and Kirkham, 1997; Galarza et al.,
2010; Aizaki et al., 2011; Keh et al., 2013; Okamoto et al., 2014].
Overall, the present analysis indicates that patients heterozygous
for a germline CBL mutation exhibit a wide phenotypic variabil-
ity partially overlapping NS. Besides the occurrence of a subtle
phenotype in a large proportion of subjects, clinical features are
particularly severe in a small number of cases. Although available
data suggest possible genotype–phenotype correlations, based on
the increasing evidence documenting co-occurrence of mutations
in functionally related genes [Nystrom et al., 2009; Tang et al., 2009;
Thiel et al., 2009; Longoni et al., 2010], the possibility that lesions
concomitant to those involving CBL might modulate the pheno-
type in some of these individuals cannot be ruled out. Analysis of
the phenotypic spectrum associated with CBL mutations indicates
thatmolecular scanningof this genewouldbeworthwhile inpatients
with facial features resembling NS associated with brain anomalies,
but normal cardiac development and growth, as well as in subjects
with NS/JMML without mutations in known disease genes.
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